KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Long-Term Investments (2016 - 2024)

Gsk (GSK) has 7 years of Long-Term Investments data on record, last reported at $1.4 billion in Q4 2024.

  • For Q4 2024, Long-Term Investments changed N/A year-over-year to $1.4 billion; the TTM value through Dec 2024 reached $1.4 billion, changed N/A, while the annual FY2024 figure was $1.4 billion, N/A changed from the prior year.
  • Long-Term Investments reached $1.4 billion in Q4 2024 per GSK's latest filing, down from $1.7 billion in the prior quarter.
  • Across five years, Long-Term Investments topped out at $1.7 billion in Q4 2022 and bottomed at $24.3 million in Q4 2021.
  • Average Long-Term Investments over 3 years is $1.1 billion, with a median of $1.4 billion recorded in 2024.
  • The widest YoY moves for Long-Term Investments: up 6991.46% in 2022, down 6991.46% in 2022.
  • A 3-year view of Long-Term Investments shows it stood at $24.3 million in 2021, then soared by 6991.46% to $1.7 billion in 2022, then fell by 17.95% to $1.4 billion in 2024.
  • Per Business Quant database, its latest 3 readings for Long-Term Investments were $1.4 billion in Q4 2024, $1.7 billion in Q4 2022, and $24.3 million in Q4 2021.